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Abstract
Studies evaluating the impact of Xpert MTB/RIF testing forBackground: 
tuberculosis (TB) have demonstrated varied effects on health outcomes
with many studies showing inconclusive results. We explored perceptions
among diverse stakeholders about studies evaluating the impact of TB
diagnostic tests, and identified suggestions for improving these studies.
 We used purposive sampling with consideration for differingMethods:
expertise and geographical balance and conducted in depth
semi-structured interviews. We interviewed English-speaking participants,
including TB patients, and others involved in research, care or
decision-making about TB diagnostics. We used the thematic approach to
code and analyse the interview transcripts.
We interviewed 31 participants. Our study showed thatResults: 
stakeholders had different expectations with regard to test impact and how
it is measured. TB test impact studies were perceived to be important for
supporting implementation of tests but there were concerns about the
unrealistic expectations placed on tests to improve outcomes in health
systems with many influencing factors. To improve TB test impact studies,
respondents suggested conducting health system assessments prior to the
study; developing clear guidance on the study methodology and
interpretation; improving study design by describing questions and
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 interpretation; improving study design by describing questions and
interventions that consider the influences of the health-care ecosystem on
the diagnostic test; selecting the target population at the health-care level
most likely to benefit from the test; setting realistic targets for effect sizes in
the sample size calculations; and interpreting study results carefully and
avoiding categorisation and interpretation of results based on statistical
significance alone. Researchers should involve multiple stakeholders in the
design of studies. Advocating for more funding to support robust studies is
essential.
TB test impact studies were perceived to be important toConclusion: 
support implementation of tests but there were concerns about their
complexity. Process evaluations of their health system context and
guidance for their design and interpretation are recommended.
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Introduction
Tuberculosis (TB) continues to be a major public health burden. 
In 2018 it was estimated that about 10 million people devel-
oped TB disease, there were about half a million new cases of 
rifampicin-resistant TB, and 1.5 million deaths due to TB1. The 
End TB strategy strives to reduce TB incidence by 80%, and TB 
mortality by 90% compared to 2015 levels. To facilitate progress 
towards these targets, the World Health Organization (WHO) 
recommends that countries aim to have 90% or more of TB 
patients diagnosed with WHO recommended rapid tests, and 90% 
or more of eligible patients treated with new recommended 
drugs by the year 20252.
In order to improve TB case detection and rapid initiation of 
treatment, new rapid molecular diagnostic tests with reported 
high sensitivity and specificity and/or short-turnaround times, 
such as Xpert MTB/RIF and Xpert Ultra (the newest version) 
continue to be introduced to the market1,3. It is expected that 
accurate diagnosis and rapid initiation of treatment would 
improve downstream health outcomes such as morbidity and 
mortality.
However there is uncertainty about the effects of Xpert MTB/
RIF on people-important outcomes, which include outcomes 
that directly reflect how an individual feels, functions or survives 
(patient health outcomes)4, and outcomes that lie on the causal 
pathway through which a test can affect a patient’s health, and 
thus predict patient health outcomes (surrogate or intermediate 
outcomes)5,6. Two recently published systematic reviews 
and meta-analyses of randomized trials suggest Xpert MTB/ 
RIF likely reduces mortality7 [odds ratio 0·88, 95% CI 0·68–1·14] 
and unfavorable treatment outcomes8 [risk ratio 0.92, 95% CI 
0.82–1.02] when compared to smear microscopy in adults with 
presumptive TB, but uncertainty in effect estimates was high. 
Pooled results in the meta-analyses suggested Xpert MTB/ 
RIF did not affect time to diagnosis [hazard ratio 1·05, 95% CI 
0·93–1·19] and time to treatment [hazard ratio 1·0, 0·75–1·32]. 
Confidence intervals were wide demonstrating large variation in 
estimates.
Randomized trials of diagnostic tests are typically considered the 
best way9 to evaluate the effects or impact of interventions but 
these studies are challenging and their interpretation may not be 
straightforward10–12. A diagnostic test is evaluated as an ele-
ment in a complex intervention, comprised of a sequence of 
interrelated events and decisions, all which vary across differ-
ent study contexts12. End users and other stakeholders may have 
different perspectives on the impact of diagnostic tests, out-
come measures that matter, and how they should be evaluated. 
To our knowledge no systematic attempts to gather and analyze 
these perspectives have been published.
Qualitative research can help in understanding the complex 
phenomena at play and the varied perceptions of participants 
who are part of TB diagnostic test studies, and help to shed light 
on why and how these tests work in different contexts, and on 
how best to implement them13 .
We explored perceptions of diverse stakeholders about studies 
evaluating the impact of TB diagnostic tests, and identified 
suggestions for improving these studies.
Methods
Study design
We conducted a qualitative study, using a phenomenologi-
cal approach, that aimed to develop a complete description 
and understanding of human experiences and meanings, allowing 
findings to emerge from the data14.
Sampling and recruitment
Participants were purposively sampled from institutions known 
to our network and from other diagnostic forums such as 
the Stop TB New Diagnostics Working Group, and the Glo-
bal Health Diagnostics community online (GHDonline). To 
source participants from GHDonline, we sent a general email to 
members on the platform inviting them to participate in the 
study. Invitation letters can be found in Extended data: Annex 1.
We only included English-speaking participants who had been 
involved in research, care, or decision making about both drug 
susceptible and drug resistant TB diagnosis. Considering that 
diagnostic tests need to function in a complex ecosystem of 
various users at various levels of the health care systems13, 
we sampled diverse stakeholders. We considered maximum vari-
ation with regard to expertise (researchers, clinicians, labora-
tory workers, TB programme managers, guideline developers, 
policy makers, TB technical assistance and support agencies, 
funding agencies, patients, TB survivors and activists) and 
geographical location (from various low and high TB burden 
countries). We believed that a diverse group of stakeholders 
would give us a broader insight in designing, executing, 
interpreting and using TB studies for decision-making.
We sent out invitations to 60 potential participants, and inter-
viewed only those who responded to, and accepted our invitation. 
We aimed to have a purposive sample of 30 participants in 
the study, since we anticipated that data saturation would have 
been reached with this number.
Data collection
Data were collected through in-depth semi-structured interviews. 
We prepared an interview guide and tailored it to the different 
stakeholders we were interviewing (Extended data: Annex 2). 
The topic guide was piloted by conducting mock interviews 
on three colleagues (not part of this project) from the Centre 
of Evidence-based health care in Stellenbosch University and 
modified based on the results of a pilot exercise.
Interviews were conducted by two researchers (EO [female] 
and SN [male]15). EO has a medical background with further 
training in international health and clinical epidemiology. SN 
is an epidemiologist. Both EO and SN underwent an additional 
three-month training course in qualitative research methods and 
interview techniques.
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Interviews were conducted in English via a conference call 
platform or by telephone. Teleconference interviews were con-
ducted by EO with SN listening in and taking notes. Face to 
face interviews were conducted with patients in Khayelitsha 
community health clinic (Cape Town) by SN with the help of a 
professional interpreter who translated questions from English 
to the local language isiXhosa. Participant responses were then 
translated back to English.
There were no pre-established relationships between the inter-
viewers and participants prior to the interviews. Participants 
were provided with information sheets and written consent 
forms prior to the interview; via Google Forms for teleconfer-
ence interviews, and hard copies for face-to-face interviews. The 
content of consent forms was similar for non-patient participants 
and patients; however consent forms for patients were translated 
into the local language isiXhosa (Extended data: Annex 3).
Interviews lasted between 30 to 45 minutes. Interview data were 
captured using a digital voice recorder. Interviews were tran-
scribed for analysis, by a professional transcriber. All transcripts 
were audited for accuracy by the interviewer who conducted 
the interview. Names of participants did not appear on the 
transcripts. Transcripts were not returned to participants for 
corrections or clarification.
Data are stored electronically in password protected computers, 
and on secure online data storage platforms.
Data analysis
Analysis of the interviews was done after data collection using 
thematic analysis16. Two researchers EO and SN coded the inter-
view transcripts together, discussing the codes and themes. EO 
and SN first familiarized themselves with the subject matter 
by listening to the audio tapes and reading the transcripts. The 
first transcript was coded independently and themes in the data 
were discussed. For feasibility reasons we decided to code 
subsequent transcripts together. Guided by the research ques-
tions, our analysis utilized deductive and inductive approaches 
grounded in the data. We did not apply line by line coding to 
every single line, but coded information that was relevant to our 
research question. We developed a broad set of codes, and 
modified or added to the codes as we read the transcripts. We 
coded the hard transcripts using the qualitative software Atlas ti. 
version 7.
We generated and merged similar codes to minimize duplication 
and improve readability and grouped the codes into sub-themes 
and themes in discussion with a senior author (MN) (see coding 
hierarchy in Extended data: Annex 4).
Ethics and reporting
This study received ethical approval from the health research 
ethics committees of Stellenbosch University (HREC 
Reference # N18/01/009) and University of Cape Town, and 
approval from the city of Cape Town to use health facilities in 
Khayelitsha. We referred to the consolidated criteria for report-
ing qualitative research (COREQ) to guide the reporting of 
this study17.
Results
We conducted 31 interviews between September and December 
2018. A summary of the study participants’ characteristics can 
be found in Table 1.
We explored four major themes: General perception of test 
impact studies, barriers facing test impact studies, selection of 
outcome measures, and suggestions for improving test impact 
studies. These themes and related subthemes have been 
summarized in Figure 1.
Table 1. Characteristics of study participants (n=31).
*Stakeholder (n) †Country
Researchers (n=9) Uganda, Zimbabwe, Malawi, South Africa, United States of 
America, United Kingdom, Canada, Australia
Clinicians (n=2) South Africa
Clinician scientists (n=2) Australia, South Africa
Policy makers (n=1) Switzerland
Technical agencies (n=1) Switzerland
Guideline developers (n=3) India, United Kingdom, Netherlands
Test developers/Industry (n=4) USA, Germany
Funders (n=1) USA
Laboratory worker (n=1) Pakistan
TB survivors/activists (n=4) South Africa, India
Patients (n=3) South Africa
*Some participants had multiple roles with regard to TB diagnostics. The stated role was based on the 
predominant role they discussed during the interview.
†Geographical location was based on their work station or institution at the time of the interview.
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Figure 1. Summary of themes and subthemes about perceptions of test impact studies.
Theme 1: General perception of test impact studies
Varied understanding of the meaning of test impact. There 
were varied responses on the meaning and understanding of 
what the impact of a test entails. One respondent noted that the 
term impact is a big term and could mean anything. This response 
was confirmed by other respondents who stated that their under-
standing of the term impact of a test included improving health, 
improving detection of drug-resistant tuberculosis (DR-TB), 
improving timely treatment through high accuracy and rapid 
test results, improving access to diagnostic testing and reducing 
transmission of TB.
“So, I mean I think impact is a big word right and exactly 
what we mean by that?”- (P7, Researcher)
Unrealistic expectations of the impact of tests on health out-
comes. Some respondents felt that the TB community has 
unrealistic expectations about the ability of tests to demonstrate 
improved health outcomes. Contextual factors in the broader 
health system influence the effectiveness of test rather than a test 
alone. For example, some felt that the issue limiting the 
effectiveness of TB tests is not the tests themselves but logistical 
issues.
“The technology alone is not the sole determinant of impact, 
but rather the other supporting elements in the ecosystem 
that are required to correctly and accurately diagnose 
patients with TB, and link them to care and on the way to 
cure”. – (P20, Funder)
“So, I think we have the wrong expectations as a community 
as well.”- (P27, Technical agency representative)
“I really look at tuberculosis as a logistics problem.” – (P13, 
Test developer)
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“It’s very frustrating when they say with confidence, we 
need more drugs more diagnostics. No you don’t. You need 
to make the system work better” - (P11, Test developer)
Test impact studies are generally important to support imple-
mentation. Respondents generally perceived that studies evaluat-
ing the impact of tests on health outcomes were important. The 
reasons to support their importance included that they were 
important mostly to support implementation strategies of tests, 
and as complementary evidence to test accuracy studies.
“Generally, I think they are important to support decisions on 
appropriate implementation strategies for different settings 
and different countries and with that also decisions on scale 
up.”- (P27, Technical agency representative)
“So the main way we make our guidance and recommendation 
to countries is really based on the diagnostic accuracy of 
particular interventions….So these are great studies to 
complement the other accuracy studies and implementation 
studies that we evaluate as part of our development of 
recommendation.” - (P5, Policy maker)
Importance of test impact studies depends on product cycle. 
Some respondents felt that the need for impact studies depends 
on the product cycle. For example, an impact study may not be 
necessary at the beginning when a test has just been developed, 
due to concerns of delaying market access of the tests. However, 
it may be necessary after roll out of a test.
“It is very difficult to use impact information in the beginning 
to make a decision to invest or not invest and so consequently 
we are willing to take the risk. Usually in a practical 
sense to invest or not invest in a technological approach 
without really understanding the feasibility of ultimately 
that technology having impact at the other end of the 
journey”. - (P20, Funder)
Theme 2: Barriers facing test impact studies
Barriers facing the design, conduct and interpretation of test 
impact studies are summarized in Figure 1 and are discussed 
below.
Design barriers
Underdeveloped methodology
Respondents felt that study designs and methods used in test 
impact studies are still not well developed, hence it is difficult to 
rely on them to guide decisions on test roll out.
“So, I think in general it is underdeveloped area….. the 
overall field of impact assessment is in its nascent state… 
impact assessments do not feature prominently in that, 
simply because they are not well articulated in a credible 
manner so as to provide reliable information to help us 
make a decision”. – (P20, Funder)
Lack of clear guidance
The lack of guidance for TB test impact studies was discussed 
by respondents.
“There was no standard way of doing this, so that was the 
overall feeling that you just had to come up with whatever 
you thought was best for the patient so a very subjective view 
in a way”. - (P1, Researcher)
Funding limitations
Funding was discussed as a major deciding factor of the 
size and duration of the test impact studies. It was noted that 
funding to support the studies was often limited.
“I think maybe it’s many funding institutions do not offer the 
amount of money you need to recruit thousands of patients 
and follow then up for years….. If you go to test like every 
variation of that intervention, you know, you end up having 
many study arms and rapidly becomes impossible to do 
the study because it is expensive and will take forever”. 
- (P12, Researcher)
Disconnect in multi-stakeholder needs
Respondents discussed the difficulties in multi-stakeholder 
collaboration in the planning and design of multifactorial impact 
studies.
“Sometimes you struggle with stakeholder support. I think 
there’s a bit of a disconnect between levels of government”. 
- (P1, Researcher)
”Well there is a disconnect between what needs to be studied, 
what is studied, who is being held accountable for the 
gaps. The diagnostic manufacturers are, often, in my view, 
being blamed for things that they did not understand were 
their jobs…” - (P11, Test developer)
Constraints related with obtaining ethical approval
Difficulties in obtaining ethical approval due to ethical concerns 
of comparing a superior test to standard of care, in resource 
limited settings, were cited as a barrier to these studies.
“Is Xpert saving lives?” But at the same time going in front 
of an ethics committee people, if you want to do a study 
let’s say of the Omni [novel point-of-care platform for 
Xpert testing] with the Xpert in comparison with standard 
of care, which is often still microscopy, people say this is 
unethical”. - (P27, Technical agency representative)
Unclear value of impact measures
Respondents felt that the value of conducting test impact 
studies was unclear due to diminished confidence in impact 
measures used in such studies, and questioned the need to con-
duct studies for effects that are deemed obvious. They felt that 
decision makers assumed that an accurate rapid test will obvi-
ously improve health outcomes by facilitating early treatment, 
hence there was no need for impact studies to show that.
“I think it’s something which the value of doing is unclear… 
but I also think the confidence that people have and the 
importance of these impact measures … has begun to be 
questioned…. So I think, you know, the argument there is 
it is intuitive and logical that if someone starts treatment 
earlier there’s probably going to benefit to their health”. 
- (P12, Researcher)
Lack of clarity in defining the intervention
Respondents cited difficulties in drawing a distinction between 
a purely diagnostic intervention and other interventions in 
test impact studies, in light of their multifactorial nature.
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“It’s difficult to draw the line about what their intervention 
is… if you are testing a diagnostic and then you are also 
SMS’ing [mobile phone messaging] your result to the patient. 
And that is not something that happens routinely. Then, you 
know, obviously your intervention is not just a diagnostic 
test …. So I think a very hard question to answer is, you 
know, where will you draw the line or definition of a 
diagnostic study versus something that is an intervention but 
includes a diagnostic”. – (P12, Researcher)
Large sample sizes
Very large sample sizes are often required for test impact 
studies, and these are often not feasible by researchers.
“I think one challenge is to make sure that there is going to 
be a sufficient number of people to actually see changes 
on patient important outcomes”. – (P19, Researcher)
Limitations in designing highly pragmatic studies
In addition, respondents cited the challenges of designing 
highly pragmatic studies in environments with resource limited 
health systems.
“One of the most difficult things to get right is to try and 
design a study that will assess …what’s going to happen 
or is happening sort of in real life, pragmatically without 
influencing sort of routine practice too much, so, pragmatic 
studies….. your comparison group is always incredibly 
difficult in real life in sort of pragmatic settings”. 
- (P28, Researcher)
Conduct barriers
Influence of health systems
The influence of, and changes in, health systems on the con-
duct of such studies, highlighted the multiple factors that face 
TB diagnostic testing.
“So at that time we were evaluating Genexpert … which 
is a really good test but it also depends on other health 
system constraints, as well (do you have the right staffing) 
and that’s what ended up happening with Genexpert. At 
some point we ran out of cartridges and it was difficult to 
get them to the country. So there are a lot of other 
complexities but then play an influence in the type of 
evaluation”. – (P16, Researcher)
“There are many changes which occur within the ministries 
and the health facilities and those may really affect the flow 
of work that you are doing and those may affect the 
implementation”. – (P17, Researcher)
“So, it’s always very difficult to attribute what is the impact 
of the actual diagnostic and around that general health 
system improvements that happened over the same time”. 
- (P28, Researcher)
Challenges in collecting samples
Other barriers faced during the conduct of these studies were: 
difficulties in accessing enough samples to evaluate the effect 
on drug resistant TB, and difficulties in accessing sputum sam-
ples in HIV infected people, in children, in very sick patients, 
and for extrapulmonary TB.
“I would say that for MTB samples we’ve still have a 
challenge with resistance samples right and that’s just 
comes down to the prevalence”. - (P13, Test developer)
“Everybody recognises the yield from bacteriological 
confirmation from young children is low and if people 
do gastric aspirates, then that is fine and if they can do 
an induced sputum then that is fine, whatever they are 
comfortable with, but the yield is low and a negative result, 
a bacteriological result doesn’t rule out TB. I think it is 
particularly more important, for example in a project 
I am working in there is a lot of drug resistant TB including 
XDRTB, children are contacts and I think we have to try 
hard in those children to get a sample for Xpert”. 
- (P6, Clinician scientist)
“Because especially when you dealing with HIV infected 
patients or with paediatrics. The type of sample becomes 
very difficult”. - (P16, Researcher)
“You cannot analyse what impact it has on the 
extrapulmonary TB case notification”. - (P8, Laboratory 
manager)
Limitations in linkage and adherence to treatment
Patients and clinicians highlighted challenges with linkage 
and adherence to treatment in routine health care settings that 
should be considered when designing TB test impact studies in real 
life settings. Without efficient processes to ensure good linkage 
and adherence to treatment, the impact of improved diagnostic 
tests will be mitigated.
“So there was no counselling me through it or nothing. 
I was basically just told that I have multi drug resistant TB 
and that I need to go to the clinic….So it was scary because 
I wasn’t really sure what was going on and I was missing 
school as well so I was anxious about that. I had an idea 
that it might be TB, but I was very much in denial about it 
you know… and just the main stumbling block for starting 
treatment is the disbelief”. - (P3, TB survivor)
“The problem is obviously adherence and once they start 
getting better out of the initial intensive phase, the need to 
keep coming back and keep continuing their treatment to 
complete the full course of treatment, adherence can be a 
challenge”. - (P6, Clinician scientist)
Pre-treatment loss to follow-up
The effect of pre-treatment loss to follow up in diluting the 
results of test impact studies was discussed.
“You would find sometimes maybe patients die before they 
actually get the result of that particular diagnosis”. - (P16, 
Researcher)
High rates of empirical therapy
The influence of high rates of empirical therapy in diluting the 
results of Xpert MTB/RIF impact studies were discussed.
“The findings are diluted by the fact that you have patients 
who are put on treatment based on clinical suspicion 
and not necessarily on the diagnostic you are evaluating 
which almost makes your diagnostic group seem like it’s 
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not working when actually it’s just people are not using 
it”. - (P16, Researcher)
Long duration of test impact studies
Some respondents felt that conducting test impact studies 
generally takes longer and would delay the introduction and 
roll out of new tests to the market.
“But I think the studies themselves are longer and if everyone 
waited for that to come out it would only prolong the 
release of diagnostics”. - (P13, Test developer)
Limitations of routine data
The challenges of routine data in pragmatic studies were also 
highlighted, including issues with requirements for many 
approvals to access data, and collecting accurate and complete 
data.
“The quality of data is out of your hands usually and it 
really depends on the system in place and if the health care 
system has special people in place to collect data and to 
record it. So what often happens in low resource settings is 
of course there is no money to hire a special person to 
collect and record and report data”. - (P18, Researcher)
Interpretation barriers
Unclear value of results of statistical significance in decision 
making
Some researchers questioned the continued endorsement of 
Xpert MTB/RIF test, despite the lack of statistically significant 
effects on mortality.
“We randomized patients to Xpert or not Xpert, and we 
expected to find a difference and found no difference over and 
over and over. And yet, despite that, we’ve continued to 
endorse Xpert…. We’ve now endorsed Ultra, even though all 
of our studies show that it does not do anything.”- 
(P31, Researcher)
“I think the decision to roll out Genexpert was predominantly 
a political decision.”- (P12, Researcher)
Theme 3: Considerations in outcome selection
Respondents proposed the outcomes they would prefer to be 
measured in TB test impact studies and commented on the 
limitations of the proposed outcomes (Table 2).
In selecting outcomes as a measure of test impact, the following 
considerations were put forward by the respondents.
Funding considerations. Funding to measure outcomes that 
can be measured early or late in the cascade of care were 
considered when selecting outcomes in impact studies.
“It goes back to that…discrepancy that I mentioned earlier 
around where…ideally you want to look at the endpoint 
that is the furthest away. But that’s also the most expensive 
right? So I, you know, I will put a lot of thought into the study 
design…I would probably encourage the person to focus on 
earlier endpoints.” - (P12, Researcher)
Statistical power of the study. The power of the study influences 
the outcomes that can be measured.
“We weren’t powered for mortality, so we looked at morbidity, 
we weren’t powered for culture conversions so we looked 
at time to treatment”. - (P12, Researcher)
Patient needs. The selection of outcomes that reflected needs 
of patients such as timeliness of care (time to diagnosis and 
time to treatment) and impact of patients’ health such as morbidity 
and mortality were mentioned.
“Help me today. Diagnose me today. Start me with treatment 
today.” - (P14, TB survivor)
“I do think the patient oriented outcomes are important and 
I think we should be looking at mortality and morbidity and 
not just the simple diagnostic accuracy, sensitivity, specificity”. 
– (P7, Researcher and guideline developer)
Sponsor and policy maker needs. Some respondents men-
tioned how study sponsors decided the outcomes of the studies 
a priori, and others discussed how the political agenda 
determined the outcomes decision makers would be interested in.
“The first thing that guided it was the study’s sponsor really. 
I am talking about one in particular where the study’s 
sponsor determined that they wanted mortality, despite 
a big study …. showing that Genexpert did not reduce 
mortality”. - (P1, Researcher)
“I think the impact metric that policy makers want to 
use is what suits the political agenda”. – (P12, Researcher)
Reflection of functioning of the health system. Intermediate 
(also known as surrogate) outcomes such as time to diagnosis 
were discussed as suitable for demonstrating the functioning and 
quality of the health system, and would thus inform roll out of 
tests.
“I’m a strong believer honestly, in surrogate outcomes 
simply because I think it holds the diagnostic tests to the 
bar of the whole health system”. – (P27, Technical agency 
representative)
Ease of measurement. The ability of an outcome measure to 
give unequivocal or unambiguous results such as mortality, and 
ease of measurement such as time to diagnosis, and time to treat-
ment were considered in selecting outcomes. For example, mor-
tality can easily be assessed because patients can be traced, 
and death can be recorded. Quality of life measurements were 
preferred by some, because standardized scores or widely accepted 
tools for measuring them exist. Morbidity was regarded as 
difficult to measure because of lack of standardized scores 
(see Table 2).
Availability and quality of data. The availability and quality of 
data was an important consideration when selecting the outcome 
to be measured. Respondents stated that analyses of outcomes 
such as ongoing transmission of infection were limited by 
availability of data. In routine settings especially, assessment 
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Table 2. Preferred outcome measures and limitations.
Preferred outcome measures Limitations
Health outcomes Clinical impact outcomes 
Composite outcome around death, 
hospitalization and undiagnosed TB 
Contact tracing 
Cost-related outcomes 
Culture conversion 
How to reduce late presentations to clinics 
Infection control 
Level of transmission 
Morbidity 
Mortality 
Outcomes measured beyond clinic 
Patient and health worker safety 
Prevalence and incidence 
Quality of life and emotional effects
Mortality 
Mortality is multifactorial and not responsibility of test 
Mortality limited by downstream effects 
Mortality limited by long follow up and funding 
Mortality limited by lost to follow up 
Mortality limited by poor routine data sources and data 
availability 
Mortality limited by study power 
Mortality may never be zero due to non-TB causes of 
death
Morbidity 
Morbidity limited by lack of standard scores 
Morbidity limited by time and resources
Cost 
Cost effectiveness preferable at population level not 
patient level 
Cost effectiveness does not convey affordability 
Cost effectiveness don’t consider holistic view 
Cost effectiveness not relevant unless there is 
beneficial effectiveness data 
Cost measurement limited by required resources and 
expertise 
Cost proxy measures for patient costs needed where 
services are free
Other health outcome 
Onward transmission outcome limited by data 
Culture conversion does not correlate with 
transmission 
Quality of life scores not applicable across cultural 
contexts
Intermediate 
outcomes
Acceptability of test and testing process 
Ease of use of tests 
Surrogate or process outcomes 
Test access 
Test accuracy 
Time to diagnosis 
Number of cases diagnosed 
Number of patients initiated on treatment 
Time to treatment as preferred outcome 
Side effects of treatment 
Treatment success 
Outcomes in whole diagnostic pathway in 
different settings
Intermediate outcome 
Test Utilization difficult to measure 
Time to diagnosis doesn’t account for wrong diagnosis 
Time to treatment not an indicator of completion of 
treatment
of mortality would be limited by loss to follow-up and poor 
routine data sources (see Table 2).
Theme 4: Suggestions for improving impact studies
Respondents suggested the following areas for consideration 
in improving impact studies;
Health system assessments prior to study. Many respond-
ents stressed the need for a thorough systems evaluation, or 
process evaluation, prior to conducting test impact studies. 
This would guide the design, conduct and interpretation of 
the impact studies, and aid more accurate attributions of a test’s 
impact.
“Well, before they do it they should comprehensively do a 
systems analysis and there are a lot of ways to do this. I 
think the patient cascade of care and the patient pathway 
should be accurately dissected so that in the journey of the 
patient from seeking healthcare to cure, that all the things 
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that could derail, assuming you have a perfect diagnostic 
test, all the other things that could derail that cure should be 
examined because at the end of the day a diagnostic test 
alone has zero impact and it simply creates a result and the 
question is how does the system deal with that result and 
how does it affect the actual delivery of care.”- (P20, Funder)
Greater guidance and support
Availing guidance for study design
The need for standardized guidelines on how to design, conduct 
and interpret such studies was suggested.
“If you have a clear guidance and a specific description 
and a standardisation that would be, I think, very beneficial, 
a beneficial guide in order to follow, so that everybody 
knows exactly what to do.” – (P23, Test developer)
Need for greater funding
Some respondents advocated for more resources to conduct 
complex impact evaluations of TB diagnostics.
“…. and the fact that they are quite difficult evaluations 
to do… So the fact that we are taking interest in this field 
is quite obviously that it is a major problem… So I think if 
you are prepared to take it on then everyone is very interested 
in the results…..And is the funds are easy to get hold of 
if you make a good case.” - (P15, Researcher)
Strengthening multi-stakeholder collaborations and support
Respondents suggested greater collaboration between produc-
ers and users of research to provide evidence that was truly 
useful to end users. They also stressed the need for collabora-
tion at all levels of health systems governance from the beginning 
of the study, in order to account for all factors that could 
influence test impact studies.
“It is quite an enabling factor in that you bring on board 
all types, you bring on board the time when we are doing 
our proposals and share our ideas and discuss with them 
and then at the end of the day, we are sure that they 
have participated their ideas have been incorporated…” 
- (P17, Researcher)
Improving study design. Respondents suggested various aspects 
to be considered when designing test impact studies, includ-
ing: improving study design by proposing diagnostic questions 
that consider the broader health care ecosystem, and measuring 
interventions that include the diagnostic test and accompanying 
clinical information, selecting the target population at the health 
care level most likely to benefit from the test, and setting realistic 
targets for outcome reduction in the sample size calculations.
“These are not the right questions. The question is can it 
perform in this environment? And so I think doing an impact 
study on usability at different levels of the health care 
system is central information for buying and fitting your 
country with the right diagnostics.”- (P11, Test developer)
“Make sure you’re measuring the right intervention, 
which is using all the information available to you, not just 
blindly doing a test without taking into account the 
relevant clinical information which is there which is fully 
available.”- (P31, Researcher)
“I think the only place to clearly demonstrate the impact on 
patient’s important outcomes tends to be when diagnostic 
tests are used among the sickest patients…. If you want 
important outcomes, then you have to be very selective 
about the population that you are going to study”. 
- (P19, Researcher)
“And, you know, to be realistic about what you were 
expecting. You often see studies where there’s quite unrealistic 
targets set in the sample size. So, it has to be well powered. 
It has to be large and you have to pick a patient group 
that you think has got the most to benefit from it.” 
- (P15, Researcher)
Need for more highly pragmatic studies
To enable decision making some respondents stressed the need 
for such studies to be designed and conducted in settings of 
intended use.
“The impact assessment needs to be done in the setting 
of intended use on the target population for which the 
intervention is likely to have the greatest impact.” - (P5, Policy 
maker)
Improving interpretation of study results.
Considering the magnitude of absolute reduction in interpretation
Improving the clarity on the implications of statistical sig-
nificance on decision making by focusing not only on 
statistical significance but the magnitude of reduction was 
discussed.
“The reduction in mortality of Xpert across an individual 
patient meta-analysis is twelve percent but it’s just not 
meeting statistical significance, but it’s twelve percent 
absolute reduction.”- (P27, Technical agency representative)
“….There’s evidence of absence, but that’s not the case, 
there’s simply absence of significant evidence, but there’s 
enough evidence to actually show that it is substantially 
impactful on surrogate outcomes and substantially impactful 
on the very important outcomes, such as mortality and it’s 
just not statistically significant… but then it comes back to 
the question that if you don’t show effect, it’s not necessarily 
the fault of the test and it doesn’t necessarily mean we 
should not roll out this test.”- (P27, Technical agency 
representative)
Discussion
Our study explored the perceptions of different stakehold-
ers about studies evaluating the effect of TB diagnostic tests on 
health outcomes, and identified suggestions for improving 
these studies. In summary, our study showed that stakehold-
ers had different expectations with regard to test impact and 
how it is measured. TB test impact studies were perceived to be 
important for supporting implementation of tests but there were 
concerns about the unrealistic expectations placed on tests to 
improve outcomes in health systems with many influencing fac-
tors. To improve TB test impact studies, respondents suggested 
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conducting health system assessments prior to the study; develop-
ing clear guidance on the study methodology and interpretation; 
improving study design by describing questions and interven-
tions that consider the influences of the health-care ecosys-
tem on the diagnostic test; selecting the target population at the 
health-care level most likely to benefit from the test; setting real-
istic targets for effect sizes in the sample size calculations; and 
interpreting study results carefully and avoiding categorisa-
tion and interpretation of results based on statistical significance 
alone. Engaging multiple stakeholders when designing these stud-
ies, advocating for more funding to support robust studies and 
conducting more highly pragmatic studies were also suggested.
Expertise and role in the health care system contribute to how 
test impact is perceived and measured5. To improve the useful-
ness of results to end-users, researchers designing the impact 
studies need to seek insights from various stakeholders involved 
in decision making about TB diagnostic tests. This will clarify 
which patient-important outcomes are considered important 
at the study design stage.
Qualitative research exploring the complex process involved 
in impact evaluations of TB tests is scarce13. Existing qualita-
tive studies about TB diagnostic tests focus mainly on stigma 
and disease perceptions influencing diagnosis13,18–22, barriers fac-
ing TB evaluation services, or TB control efforts and factors 
influencing delays in TB diagnosis15,23–26. These studies nonethe-
less give insight on the health system barriers that may affect the 
implementation of TB diagnostic tests, and indirectly flag aspects 
that researchers ought to consider when designing and conduct-
ing TB implementation trials in routine settings. For example 
Cattamanchi and colleagues25 demonstrated that health system 
barriers (stock outs, limited infrastructure, poor staff motiva-
tion, high workload, poor coordination of health services) and 
setting barriers (stigma, patient time and costs) both impede TB 
diagnosis, and if not addressed could impede TB case detection. 
Indeed, one respondent in our study cited stock outs in Xpert 
MTB/RIF cartridges as a challenge that delayed their impact 
study. Unavailability of tests could contribute to high rates of 
empirical therapy in a study, mitigating the effect of Xpert on 
mortality.
Since the initial recommendations for the use of Xpert MTB/
RIF in 201027, we still lack strong evidence of the test’s impact 
on people important outcomes28. Calls have been made to better 
understand how to implement and evaluate this test (as well as 
the newest version, Xpert Ultra) in weak health systems28,29. 
The effective implementation of Xpert MTB/RIF has been lim-
ited by funding, lack of comprehensive diagnostic implementa-
tion plans, evaluations suggesting limited impact and weak health 
systems29–31. The design and execution of implementation tri-
als evaluating the effect of Xpert MTB/RIF (and Xpert Ultra) on 
health outcomes thus needs to consider the health ecosystem in 
which the test is expected to perform28,30,32. This could be done by 
incorporating process evaluations33,34 before or alongside the tri-
als to understand the different diagnostic implementation proc-
esses, and how the diagnostic interventions and the health 
ecosystem interact with each other in the TB cascade of care. 
Qualitative research methods33 incorporated in these process evalu-
ations can explain how interventions work, why interventions do 
not work, and explore factors influencing the delivery and imple-
mentation of an intervention. Process evaluations have been 
used to inform the design of trials evaluating the impact of 
malaria diagnostic tests35,36. For example, Ansah and colleagues35 
evaluated the impact of malaria rapid diagnostic tests on fever 
management in Ghana. To inform their study design they con-
ducted a baseline study of available antimalarial drugs and also 
conducted focus group discussions to explore the acceptability 
of their intervention and how best to introduce it.
The updated recommendations on the use of Xpert MTB/RIF 
advised that impact evaluations be done, but did not provide 
detailed guidance on how to do so30,37. To design effective imple-
mentation trials and impact evaluations, guidance informed by 
programmatic data specific to real life settings is needed. The 
impact assessment framework for TB diagnostic tests proposed 
by Mann and colleagues38 discussed areas and different types 
of analyses (effectiveness, equity, health systems, scale-up and 
policy analyses) to be considered in impact assessments in gen-
eral. This framework was however not specific to trials or studies 
evaluating the impact of TB diagnostic tests on health outcomes. 
Schumacher and colleagues described the range of study designs 
that can be used to assess the impact of TB diagnostics but did 
not provide guidance on how to conduct such studies6. Guid-
ance on designing effective impact trials of TB diagnostic 
tests could address areas highlighted in the findings of our study 
including how to use a priori process evaluations to guide the 
design of impact studies, and how to improve the study design 
by defining the diagnostic intervention, setting realistic targets 
in sample size calculations, selecting appropriate target popu-
lations, and guiding the selection of outcomes to be measured. 
Such guidance could also suggest how to incorporate the views 
of different stakeholders in the design and conduct of the 
impact studies and offer direction on how these studies can best 
be interpreted.
Our study had a number of strengths. We incorporated views 
from various stakeholders, including patients, to obtain a holis-
tic view of the multi factorial components of test impact studies 
and we followed the COREQ guidelines in reporting our study. 
Our study was however limited by the fact that we interviewed 
only those who responded to our invitations. Participant bias 
where respondents give expected and socially desirable answers 
could also have occurred. We tried to mitigate this by asking open 
ended questions. Most stakeholders interviewed were based 
in high-income countries, or from India and several countries 
in Africa including South Africa, Malawi, Zimbabwe and Uganda. 
This could limit the applicability of our findings. Most respond-
ents gave their perceptions about Xpert MTB/RIF. We did not 
explore perceptions of studies evaluating the effect of a point 
of care urine based lipoarabinomann assay (LAM) on health 
outcomes. Trials evaluating the impact of this test have also 
shown variation in effects on health outcomes with some 
demonstrating conclusive reduction on mortality39 and others 
inconclusive effects when TB LAM40 is compared to stand-
ard of care. Nonetheless, the effect size for LAM in those 
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trials was about a 10-20% mortality reduction similar to Xpert 
MTB/RIF7,8,39,40. Perceptions and insights explaining the signifi-
cant effects of the TB LAM test would also be useful in guiding 
the design of impact evaluations of novel TB diagnostic tests.
In summary, TB test impact studies were perceived to be impor-
tant to support implementation of tests but there were concerns 
about their complexity and how they are influenced by the 
health system context. Process evaluations of their health system 
context and guidance for their design and interpretation are 
recommended.
Data availability
Underlying data
Ethical approval from the ethics committees and informed 
consent by participants was granted to disseminate de-identi-
fied data. Relevant de-identified quotes to support the results 
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vided because information contained in the transcripts can betray 
the identity of participants. Any further requests for particular 
de-identified data or quotes can be granted by contacting the 
corresponding author directly.
Extended data
Open Science Framework: Qualitative study: Improving the 
design of impact studies for TB diagnostic tests”, https://doi.
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Reporting guidelines
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ing the design of studies evaluating the impact of diagnos-
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Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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